A study on siddha medicine Swasakudori Chenduram forSilathuma kaasam(Humid asthma)

Phase 2

• Conditions: Health Condition 1: J00-J99- Diseases of the respiratory system

• Registration Number: CTRI/2020/07/026643
• Lead Sponsor: Ayothidoss Pandithar Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Age 19 to 60 years

2.Sex: female, male, Transgender

3.Moderate persistent type of Bronchial Asthma

4.Weekly twice or daily symptoms of difficulty in breathing, Tightness of chest, Wheeze - Added sound (Rhonchi), cough with or without expectoration

5.FEV1/FVC reduced 5 percentage

6.Exacerbation is two or more in a year

7.Night time wheezing more than one day/week.

8.Obstructive type of asthma

9.Reversible by bronchodilators.

10.Asthma sometimes interferes with normal daily activities.

11.Patient who are willing to take radiological investigation and provide blood for lab investigation.

12.Patient who is willing to estimate volume of air forcibly expired after a deep inspiration by using Pulmonary Function Test.

Exclusion Criteria

1.Restrictive lung disease

2.Tuberculosis

3.COPD

4.Lung Carcinoma and other Carcinomas

5.Status asthmatics

6.Emphysema

7.Pleural effusion

8.Cardiac disease

9.Hypertension

10.Renal disease

11.Diabetic mellitus

12.Recent abdominal, thoracic, or eye surgery

13.Symptoms of acute severe illness like Chest pain, nausea, vomiting, high fever, dyspnea

14.Recent hemoptysis

15.Pneumothorax

16.Recent history of abdominal, thoracic, or cerebral aneurysm

17.Sleep apnoea

18.Pregnancy

19.Lactation

20.Psychological factor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome is assessed by comparing the lung volumes and capacities in pre and post treatment pulmonary function test. <br/ ><br> <br/ ><br>Timepoint: 6 months <br/ ><br> <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
1.Secondary outcome is assessed by comparing the parameters, before and after treatment <br/ ><br>2.Relieving of other clinical symptoms. <br/ ><br> <br/ ><br>3.Evaluating clinical lab parameters including ,AEC. <br/ ><br>Timepoint: 6 months